Navigation Links
New drugs show promise for preventing 'absence seizures' in children: UBC research
Date:2/15/2012

A team led by a University of British Columbia professor has developed a new class of drugs that completely suppress absence seizures a brief, sudden loss of consciousness in rats, and which are now being tested in humans.

Absence seizures, also known as "petit mal seizures," are a symptom of epilepsy, most commonly experienced by children. During such episodes, the person looks awake but dazed. The seizures, arising from a flurry of high-frequency signals put out by the neurons of the thalamus, can be dangerous if they occur while a person is swimming or driving, and can also interrupt learning.

Available medications don't completely control such seizures in many patients. They also cause severe side effects, including sleepiness, blurred vision and diminished motor control.

A Canadian-Australian team, led by neuroscientist Terrance P. Snutch, a Canada Research Chair in the Michael Smith Laboratories at UBC, developed new drugs with a different target the flow of calcium into brain cells. Their findings were published today in Science Translational Medicine.

The new drugs, known as Z941 and Z944, block the flow of calcium ions into those neurons. When given to rats with absence epilepsy, they suppressed seizures by 85 to 90 per cent.

The team, which included collaborators at Zalicus Pharmaceuticals Ltd. of Vancouver and the University of Melbourne, was surprised to find that when seizures did occur, they were also of shorter duration; existing medications don't have any effect on the length of seizures.

The first phase of human clinical trials of Z944 began in December, with results expected later this year.

"Z941 and Z944 were designed to target a specific type of nerve cell calcium channel associated with epilepsy, as well as other hyper-excitability disorders such as chronic pain," says Snutch, a professor in the departments of psychiatry and zoology. "The dramatic effect of the drugs in rats with absence epilepsy, together with the drugs' ability to be administered orally and easily absorbed, and its good safety profile in animals, provide us with cautious optimism for the current clinical trial."


'/>"/>
Contact: Brian Kladko
brian.kladko@ubc.ca
604-827-3301
University of British Columbia
Source:Eurekalert

Related biology technology :

1. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
2. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
3. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
4. Malaria discovery gives hope for new drugs and vaccines
5. Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
6. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
7. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
8. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
9. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
10. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
11. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... , ... Sourcing custom glass or quartz parts can be a daunting task. ... execute your job can take many hours of emails, phone calls and on-line research. ... showcase the company’s capabilities and core custom categories, and enables you to start the ...
(Date:7/18/2017)... ... July 18, 2017 , ... G-CON today announced ... Trademark Office for its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, ... applications further expand the protection of G-CON’s R&D investments and validate the G-CON ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the 2017 ... of the Allotrope Framework for commercial use. , The Bio-IT World Best Practices ... elevate the critical role of information technology in modern biomedical research, but also ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse ... testing capabilities to encompass the full series of ISO 80369 standard test procedures. ... for medical device and drug delivery systems. With this recent expansion, Whitehouse Labs ...
Breaking Biology Technology:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):